Rituximab® and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

被引：0
|
作者：
Castro, JE
Bole, J
Prada, CE
Kipps, TJ
机构：
[1] Univ Calif San Diego, John & Rebecca Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Chron Lymphocyt Leukemia Res Consortium, CRC, San Diego, CA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2518
引用
收藏
页码：690A / 690A
页数：1
相关论文
共 50 条
  • [31] Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
    Dretzke, J.
    Barton, P.
    Kaambwa, B.
    Connock, M.
    Uthman, O.
    Bayliss, S.
    Meads, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 19 - 26
  • [32] A phase Ib/II study of obinutuzumab and high-dose methylprednisolone (HDMP) for therapy of patients with chronic lymphocytic leukemia (CLL)
    Castro, Januario
    Choi, Michael Y.
    Amaya-Chanaga, Carlos I.
    Nguyen, Natalie
    Ale-Ali, Amine
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2015, 56 : 18 - 19
  • [33] A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Castro, Januario E.
    Olivier, Loria J.
    Robier, Aguillon A.
    Danelle, James
    Carlos, Suarez J.
    Bi-Ying, Yeh
    Thomas, Kipps J.
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [34] The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 110 - 118
  • [35] Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Veliz, Marays
    Pinilla-Ibarz, Javier
    CANCER CONTROL, 2012, 19 (01) : 37 - 53
  • [36] Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia
    Simkovic, Martin
    Motyckova, Monika
    Belada, David
    Vodarek, Pavel
    Kapoor, Rahul
    Jaffar, Hamna
    Vrbacky, Filip
    Zak, Pavel
    Smolej, Lukas
    ARCHIVES OF MEDICAL SCIENCE, 2016, 12 (02) : 421 - 427
  • [37] Lenalidomide and Rituximab For The Treatment Of Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results Of Planned Interim Analysis
    Choi, Michael Y.
    Castro, Januario E.
    Hoff, Sheila
    Li, Hongying
    Rassenti, Laura
    James, Danelle F.
    Messer, Karen
    Kipps, Thomas J.
    BLOOD, 2013, 122 (21)
  • [38] A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens
    Castro, Januario E.
    Loria, Olivier J.
    Aguillon, Robier A.
    James, Danelle
    Llanos, Cesar A.
    Rassenti, Laura
    Wood, Brian A.
    Homlund, Jon T.
    Kipps, Thomas J.
    BLOOD, 2007, 110 (11) : 917A - 918A
  • [39] PRACTICAL MANAGEMENT AND CARE FOR PATIENTS TAKING VENETOCLAX FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA.
    Battiato, Kristen
    Paradis, Heather Brumbaugh
    Alton, Peggy
    Alter, Debbie
    Miale-Mayer, Donna
    Llerandi, Diane
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [40] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    HAEMATOLOGICA, 2014, 99 : 589 - 589
12345